Company Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.
The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's.
ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
| Country | United States |
| IPO Date | May 27, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 620 |
| CEO | Catherine E. Owen Adams |
Contact Details
Address: 12830 El Camino Real San Diego, California United States | |
| Website | https://www.acadia-pharm.com |
Stock Details
| Ticker Symbol | ACAD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001070494 |
| CUSIP Number | 004225108 |
| ISIN Number | US0042251084 |
| Employer ID | 06-1376651 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Catherine E. Owen Adams | Chief Executive Officer & Director |
| Jennifer J. Rhodes J.D. | Executive Vice President, Chief Legal Officer & Secretary |
| Mark C. Schneyer | Executive Vice President & Chief Financial Officer |
| Rob Ackles | Senior Vice President & Chief People Officer |
| Albert S. Kildani | Senior Vice President of Investor Relations & Corporate Communications |
| Benir Ruano | Senior Vice President of Technical Development, Operations & Quality |
| Brendan P. Teehan | Non-Executive Employee |
| Dr. Elizabeth H.Z. Thompson Ph.D. | Executive Vice President and Head of Research & Development |
| James K. Kihara | Vice President, Chief Accounting Officer & Corporate Controller |
| Stephen R. Davis J.D. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 4 | Filing |
| Dec 10, 2024 | 3 | Filing |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 19, 2024 | 4 | Filing |
| Nov 19, 2024 | 4 | Filing |
| Nov 19, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 06, 2024 | 8-K | Current Report |